American Fusion Expands IP Strategy With 20 Texatron Patent Filings

GlobeNewswire Inc.GlobeNewswire Inc.
|||1 min read
Key Takeaway

American Fusion files 20 Texatron patent applications, with 240 more planned through 2026, totaling approximately 260 applications to protect its aneutronic fusion technology.

American Fusion Expands IP Strategy With 20 Texatron Patent Filings

Renewal Fuels, Inc. (OTC: RNWF), operating under the American Fusion brand, has filed 20 patent applications with the U.S. Patent and Trademark Office covering its Texatron™ aneutronic fusion technology platform. The filings focus on the company's proprietary "clam-shell" reactor architecture, which represents a key component of its intellectual property strategy in the emerging fusion energy sector.

The company is currently developing approximately 240 additional patent applications in collaboration with Chief Technology Officer Dr. John Brandenburg. American Fusion plans to submit these applications in phases throughout 2026 and beyond, with the goal of establishing a comprehensive patent portfolio encompassing approximately 260 total applications. This phased approach allows the company to systematically protect various aspects of its technology across multiple jurisdictions and technical domains.

The Texatron™ platform utilizes Helium-3 and Deuterium as fuel sources, designed to minimize neutron radiation in fusion reactions. The technology incorporates a compact, modular architecture intended to enable scalable deployment across various applications. The expansion of the company's patent portfolio reflects its commitment to protecting its technological innovations as it advances its aneutronic fusion development efforts.

Source: GlobeNewswire Inc.

Back to newsPublished Feb 27

Related Coverage

GlobeNewswire Inc.

American Fusion Reaches Key Milestone as 5MW Texatron Nears Testing Phase

American Fusion Inc. completes 5MW Texatron structural frame in Texas and launches $5 million fundraise to support testing and system integration milestones.

AMFN
Benzinga

ITC Bans Innoscience GaN Imports in Victory for Infineon's Patent Fortress

U.S. trade body rules against Innoscience in patent dispute, ordering import and sales bans on gallium nitride products. Decision faces 60-day presidential review.

IFNNY
GlobeNewswire Inc.

Cerence Takes Amazon to ITC Over Conversational AI Patent Infringement

Cerence files ITC complaint against Amazon, alleging patent infringement in smart devices. Seeks exclusion order blocking imports of infringing products.

AMZNCRNC
GlobeNewswire Inc.

Lilly's Retatrutide Hits Surgery-Level Weight Loss, But IP Wars Loom

Eli Lilly's retatrutide achieved 28.7% mean weight loss, matching bariatric surgery. However, competitive pressures from Novo Nordisk, Pfizer, and others are intensifying.

PFELLYSNY
Benzinga

Anixa Biosciences Secures Mexican Patent for Breast Cancer Vaccine Through 2040

Anixa Biosciences secures Mexican patent for breast cancer vaccine extending protection through 2040, supporting Phase 2 trial advancement.

ANIX
Benzinga

Xiao-I Defeats Apple in China AI Patent Battle, Shares Surge 32%

$AIXI surges 32% after China's Supreme Court rejects Apple's patent challenge, validating Xiao-I's AI intellectual property and strengthening its negotiating position.

AAPLAIXI